Publication details
Doporučený postup diagnostiky a léčby infekce virem hepatitidy B
| Title in English | Recommended procedure for diagnosis and treatment of infection of virus hepatitis B |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Gastroenterologie a hepatologie |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.14735/amgh2017419 |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | hepatitis B; chronic entecsvic; tenofovir disoproxii fumarate; tenofovir aiafenamide; pegylated interferon alfa |
| Description | The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September, 2014. The basis for these guidelines are the European Association for the Study of the Liver guidelines of April, 2017. According to recent estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevaient study, 0.56% of Czech citizens were chronically infected with HBV in 2001. A similar study in 2013 performed in only two regions of the Czech Republic found a prevalence rate of only 0.064%. HBV infection can lead to serious life-threatening liver damage, such as fulminant hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). The main goal of treatment is to prolong and improve quality of life for the patient by preventing progression from chronic hepatitis to cirrhosis, cirrhosis decompensation, and development of HCC. This goal can be achieved if HBV replication is suppressed in & sustained manner. Additional goals are the prevention of vertical transmission from mother to newborn, inhibition of HBV reactivation, and the development of a therapy for HBV-reiated extrahepatic manifestations. |